☰

Amanda J. Redig, Ph.D. - Publications

Affiliations: 
2009 Integrated Graduate Program in the Life Sciences Northwestern University, Evanston, IL 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Guerra SL, Maertens O, Kuzmickas R, De Raedt T, Adeyemi RO, Guild CJ, Guillemette S, Redig AJ, Chambers ES, Xu M, Tiv H, Santagata S, Jänne PA, Elledge SJ, Cichowski K. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell. PMID 32243838 DOI: 10.1016/J.Ccell.2020.03.004  0.411
2018 Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. Jama Oncology. PMID 30073261 DOI: 10.1001/Jamaoncol.2018.2969  0.375
2018 Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, ... ... Redig AJ, et al. Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30072474 DOI: 10.1158/1078-0432.Ccr-18-0876  0.351
2018 Awad MM, Bahcall M, Sholl LM, Wilson FH, Paweletz C, Capelletti M, Leonardi GC, Watanabe M, Baba H, Chambers ES, Redig AJ, Nishino M, VanderLaan PA, Costa DB, Imamura Y, et al. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 9069-9069. DOI: 10.1200/Jco.2018.36.15_Suppl.9069  0.404
2018 Köhler J, Gokhale PC, Li J, Wilkens MK, Tiv H, Bhagwat SV, Donoho G, Brueck P, Tiu RV, Redig AJ, Chambers ES, Ogino A, Choi J, Xu M, Kirschmeier P, et al. Abstract 5467: Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models Cancer Research. 78: 5467-5467. DOI: 10.1158/1538-7445.Am2018-5467  0.471
2017 Redig AJ. Raising the bar: the future of EGFR inhibition in non-small lung cancer. Translational Lung Cancer Research. 6: S58-S61. PMID 29299413 DOI: 10.21037/Tlcr.2017.10.09  0.375
2017 Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, et al. Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6. PMID 29087937 DOI: 10.7554/Elife.33173  0.383
2017 Kosaka T, Tanizaki J, Paranal R, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig A, Bahcall M, Oxnard GR, Eck M, et al. Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Research. PMID 28363995 DOI: 10.1158/0008-5472.Can-16-3404  0.336
2017 Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, et al. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6. PMID 28145866 DOI: 10.7554/Elife.18970  0.536
2017 Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, et al. Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer Elife. DOI: 10.7554/Elife.18970.029  0.388
2017 Redig A, Chambers E, Lydon C, Alden R, Jänne P. P1.02-054 Genomic Complexity in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) by Smoking Status with Comparison to EGFR Mutant NSCLC: Topic: Driver Genes in NSCLC, Resistance, and Other Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.638  0.309
2016 Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. Jama Oncology. PMID 27387964 DOI: 10.1001/Jamaoncol.2016.1304  0.305
2016 Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Targeting bet bromodomain proteins in solid tumors. Oncotarget. PMID 27283767 DOI: 10.18632/Oncotarget.9804  0.385
2016 Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27281561 DOI: 10.1158/1078-0432.Ccr-16-0909  0.326
2016 Redig AJ, Jänne PA. No Target Left Behind: Improving Therapeutic Options for ERBB2-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: 784-6. PMID 27211578 DOI: 10.1016/J.Jtho.2016.04.009  0.432
2016 Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach SL, Fontes C, Shi Y, Chalasani P, Janne PA. Clinical and molecular characteristics of NF1 mutant lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26861459 DOI: 10.1200/Jco.2015.33.15_Suppl.8022  0.312
2016 Redig AJ, Chambers ES, Lydon CA, Dahlberg SE, Alden RS, Janne PA. Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers. Journal of Clinical Oncology. 34: 9087-9087. DOI: 10.1200/Jco.2016.34.15_Suppl.9087  0.324
2016 Palakurthi S, Xu M, Redig AJ, Dills M, Gokhale P, Choi J, Ogino A, Kuang Y, Feeney N, Paweletz C, Kirscmeier P, English J, Cross D, Jänne P. Abstract 5192: Utilizing NSCLC PDXs derived from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies Cancer Research. 76: 5192-5192. DOI: 10.1158/1538-7445.Am2016-5192  0.349
2015 Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 975-7. PMID 25667288 DOI: 10.1200/Jco.2014.59.8433  0.371
2015 Redig AJ, Taibi M, Oxnard GR, Boucher D, Rabin MS, Marcoux JP, Gandhi L, Huberman M, Rangachari D, Lucca JV, Morse LK, Andan M, Johnson BE, Costa DB, Janne PA, et al. A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression. Journal of Clinical Oncology. 33: 8076-8076. DOI: 10.1200/Jco.2015.33.15_Suppl.8076  0.326
2015 Gokhale PC, Palakurthi S, Xu M, Calles A, Shah SD, O'Connell A, Messineo M, Kuang Y, Yanagita M, Ali M, Tran CA, Choi J, Ogino A, Butaney M, Redig AJ, et al. Abstract 1451: Modeling patient-derived lung cancer in mice: Preclinical tool for drug development Cancer Research. 75: 1451-1451. DOI: 10.1158/1538-7445.Am2015-1451  0.306
2015 Akbay EA, Koyama S, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Fecci PE, Johnson BE, Janne PA, et al. Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B96  0.304
2015 Palakurthi SS, Xu M, Redig A, Dills M, Gokhale P, Choi J, Ogino A, Kuang Y, Feeney N, Paweletz C, Kirschmeier P, English J, Cross D, Janne PA. Abstract A105: Credentialing the concept of “co-clinical trials”: Utility of lung cancer PDX models derived from patients on AZD9291 clinical trials Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A105  0.354
2011 Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4378-88. PMID 21415215 DOI: 10.1158/1078-0432.Ccr-10-2285  0.555
2011 Redig AJ, Vakana E, Platanias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leukemia & Lymphoma. 52: 45-53. PMID 21299459 DOI: 10.3109/10428194.2010.546919  0.765
2009 Joshi S, Kaur S, Redig AJ, Goldsborough K, David K, Ueda T, Watanabe-Fukunaga R, Baker DP, Fish EN, Fukunaga R, Platanias LC. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proceedings of the National Academy of Sciences of the United States of America. 106: 12097-102. PMID 19574459 DOI: 10.1073/Pnas.0900562106  0.762
2009 Redig AJ, Sassano A, Majchrzak-Kita B, Katsoulidis E, Liu H, Altman JK, Fish EN, Wickrema A, Platanias LC. Activation of protein kinase C{eta} by type I interferons. The Journal of Biological Chemistry. 284: 10301-14. PMID 19211565 DOI: 10.1074/Jbc.M807254200  0.581
2008 Redig AJ, Platanias LC. Protein kinase C signalling in leukemia. Leukemia & Lymphoma. 49: 1255-62. PMID 18604714 DOI: 10.1080/10428190802007726  0.578
2008 Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Platanias LC. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. The Journal of Biological Chemistry. 283: 12034-42. PMID 18299328 DOI: 10.1074/Jbc.M708816200  0.702
2008 Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, Platanias LC. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. The Journal of Biological Chemistry. 283: 1992-2001. PMID 18048359 DOI: 10.1074/Jbc.M705227200  0.783
2008 Altman JK, Glaser H, Redig A, Sassano A, Tallman MS, Platanias LC. Targeting the Mnk Pathway Enhances Chemotherapy-Induced Antileukemic Responses. Blood. 112: 1617-1617. DOI: 10.1182/Blood.V112.11.1617.1617  0.682
2007 Redig AJ, Platanias LC. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 27: 623-36. PMID 17784814 DOI: 10.1089/Jir.2007.0007  0.601
2007 Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Research. 67: 4524-32. PMID 17483369 DOI: 10.1158/0008-5472.Can-06-3686  0.625
2006 Yoon P, Giafis N, Smith J, Mears H, Katsoulidis E, Sassano A, Altman J, Redig AJ, Tallman MS, Platanias LC. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Molecular Cancer Therapeutics. 5: 2815-23. PMID 17121928 DOI: 10.1158/1535-7163.Mct-06-0263  0.692
2006 Altman JK, Sassano A, Yoon PJ, Redig AJ, Katsoulidis E, Tallman MS, Platanias LC. Targeting the mTOR Pathway Suppresses the Growth of Acute Myeloid Leukemia (AML) Progenitors and Enhances Arsenic Trioxide Induced Antileukemic Responses. Blood. 108: 1898-1898. DOI: 10.1182/Blood.V108.11.1898.1898  0.778
Show low-probability matches.